Polyrizon Starts GMP Mfg for Allergy Blocker
Ticker: PLRZ · Form: 6-K · Filed: Jan 23, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: manufacturing, clinical-trial, drug-development, press-release
TL;DR
Polyrizon kicks off GMP manufacturing for its PL-14 allergy blocker, aiming for 2025 clinical trials.
AI Summary
Polyrizon Ltd. announced on January 23, 2025, that it has begun the Good Manufacturing Practice (GMP) preliminary process for its PL-14 Allergy Blocker. This manufacturing step is in preparation for a planned clinical trial in 2025. The company is a foreign private issuer incorporated in Israel.
Why It Matters
This marks a significant step towards clinical trials for Polyrizon's PL-14 allergy treatment, potentially paving the way for future product approval and market entry.
Risk Assessment
Risk Level: medium — The company is in the early stages of drug development, with success dependent on clinical trial outcomes and regulatory approvals.
Key Numbers
- 2025 — Clinical Trial Year (Planned year for the PL-14 clinical trial)
Key Players & Entities
- Polyrizon Ltd. (company) — Filer of the 6-K report and developer of PL-14
- PL-14 (product) — Polyrizon's allergy blocker
- January 23, 2025 (date) — Date of the press release and filing
- 2025 (date) — Year of planned clinical trial
- 001-42375 (company) — Commission file number for Polyrizon Ltd.
- 333-284410 (company) — File number for Polyrizon's Registration Statement on Form S-8
FAQ
What is the specific status of the GMP preliminary process for PL-14?
The filing states that Polyrizon has commenced the GMP preliminary process, indicating the initiation of manufacturing steps under strict quality control for its PL-14 Allergy Blocker.
When is the PL-14 clinical trial expected to take place?
The clinical trial for PL-14 is planned for 2025.
What is the purpose of this Form 6-K filing?
This Form 6-K filing incorporates by reference a press release issued by Polyrizon Ltd. on January 23, 2025, announcing the commencement of GMP manufacturing for its PL-14 Allergy Blocker.
What is the company's primary business sector?
Polyrizon Ltd. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Polyrizon Ltd. headquartered?
Polyrizon Ltd. is headquartered at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2025-01-23 08:59:02
Filing Documents
- ea0228483-6k_polyrizon.htm (6-K) — 10KB
- ea022848302ex99-1_polyrizon.htm (EX-99.1) — 12KB
- 0001213900-25-005713.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: January 23, 2025 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2